We present evidence that pyrrolidine dithiocarbamate (PDTC) inhibits growth of p53-negative pancreatic adenocarcinoma cell lines via cell cycle arrest in the S-phase, while it has no effect on primary fibroblast proliferation. Growth inhibition of cancer cells is dependent on ROS and ERK1/2 induction as indicated by a significantly reduced PDTC-associated growth inhibition by the free radical scavenger N-acetyl-L-cysteine (NAC) or the MEK/ERK1/2 inhibitor (PD98059). Moreover, ERK1/2 induction is dependent on ROS production as demonstrated by a complete removal of PDTC-mediated ERK1/2 phosphorylation by NAC. p21 WAF1/CIP1 activation has a central role in growth inhibition by PDTC, as revealed by P21 WAF1/CIP1 silencing experiments with antisense oligonucleotide, and occurs via increased mRNA stability largely mediated by ROS/ERK induction. Conversely, PDTC does not affect P21 WAF1/CIP1 gene expression in primary fibroblasts, although it is able to activate p53 and the p53-regulated antioxidant SESN2. These results suggest that the resistance of fibroblasts to the cytotoxic action of PDTC may be related to the upregulation of p53-dependent antioxidant genes. Finally, in vivo studies on PaCa44 cells subcutaneously xenografted in nude mice show that treatment with 100 or 200 mg/kg PDTC reduces of 30% or 60% the tumour volume, respectively, and does not cause any apparent form of toxicity.
Introduction
Pyrrolidine dithiocarbamate (PDTC) is a synthetic low-molecular-weight thiol compound that has been initially described as an antioxidant agent [1, 2] . However, due to its ionophore properties [3, 4] or the possibility to be enzymatically converted into the reactive intermediate sulfenic acid [5] , PDTC may also act as a pro-oxidant agent in vivo.
It has been reported that the antioxidant activity of PDTC induces apoptosis in some tumour cell lines, such as colorectal [2] and prostatic carcinoma cells [6] , but may also lead to a reduction of cell growth inhibition of colorectal cancer cells by photosensitization [7] .
Similarly, the pro-oxidant activity of PDTC has been described to induce cell death in human acute myelogenous leukemic cells [8] , but also cell proliferation in a murine thymoma cell model [9] . Therefore, PDTC may be considered as a functionally versatile molecule, which determines either cell death or cell death prevention depending on the specific cellular model and micro-environment.
Although the molecular mechanisms underlying PDTC action are not completely understood, the induction of specific genes is thought to be responsible for the specific effects on cell proliferation. One key event for the antiproliferative activity of PDTC seems to be the activation of P21 WAF1/CIP1 [2] , following a pathway independent of p53, the main transcriptional activator of P21 WAF1/CIP1 [10] . The present study was initiated to investigate whether PDTC was able to inhibit the growth of p53-negative human pancreatic adenocarcinoma cell lines. Indeed, pancreatic cancer is characterized by alterations at high frequency in TP53 [11] , whereas it is generally wild type for P21 WAF1/CIP1 . Despite advances in the understanding of its molecular biology, gold standard chemotherapy (5-fluorouracil or gemcitabine) is largely ineffective [12, 13] and prognosis remains dismal with a 5-year survival of less than 5% [14] .
Herein, we show that PDTC specifically inhibits pancreatic adenocarcinoma cell growth in vitro by P21 WAF1/CIP1 mRNA stabilization mediated by ROS dependent ERK1/2 induction, while it has no effect on fibroblast proliferation. The latter effect is most likely due to the ROS scavenging activity of sestrin 2 induced by PDTC-activated p53. We further report that PDTC treatment significantly inhibits the growth of xenografted pancreatic adenocarcinoma cells in nude mice.
Materials and methods

Chemicals
Pyrrolidine dithiocarbamate (PDTC) and N-acetyl-L-cysteine (NAC) (Sigma) were freshly prepared in sterile water. Trichostatin A (TSA) (Sigma) was prepared in absolute ethanol and stored at −80°C until use. Diethylmaleate (DEM) was purchased from Sigma. PD98059, JNK Inhibitor II, SB203580 (Calbiochem) were prepared in DMSO and stored at −20°C until use. Actinomycin D (Sigma) was prepared in sterile water and stored at −20°C until use.
Cell culture
Four human pancreatic adenocarcinoma cell lines were studied: PaCa44, T3M4, Panc1, and CFPAC1 (see [11] for genetic characterization and primary tissue source). All cell lines were grown in RPMI 1640 supplemented with 20 mM glutamine, 10% FBS and 50 μg/ml gentamicin sulfate (BioWhittaker) and were incubated at 37°C with 5% CO 2 . Primary fibroblasts were grown in DMEM supplemented with 20 mM glutamine, 10% FBS and 50 μg/ml gentamicin sulfate and were incubated at 37°C with 5% CO 2 .
Cell proliferation assay and P21
WAF1/CIP1 silencing Cells were plated in 96-well plates (4 × 10 3 cells/well) and after 24 h treated with the appropriate compounds (see figure legends) that were left in the medium for 24 h; then cells were stained with crystal violet (Sigma). The dye was solubilised in PBS containing 1% SDS and measured photometrically (A 595 nm ) to determine cell viability. The phosphorothioate oligonucleotides for P21 WAF1/CIP1 silencing experiments, obtained from Invitrogen, were: antisense oligonucleotide (p21 AS), 5′-TCCCCAGCCGGTTCTGACAT-3′, sense oligonucleotide (p21 S), 5′-ATGTCAGAACCGGCTGGGGA-3′. Cells were treated for 24 h with 0.2 μM phosphorothioate oligonucleotides in presence or absence of 250 μM PDTC and then stained with crystal violet.
Cell cycle analysis
Cell cycle distribution was analyzed using propidium iodide (PI)-stained cells. Briefly, 2 × 10 5 cells were washed with PBS, incubated with 0.1% sodium citrate dihydrate, 0.1% Triton X-100, 200 μg/ml RNase A, 50 μg/ml propidium iodide (Roche Molecular Biochemicals) and analyzed using a flow cytometer (FACScalibur, Becton Dickinson, Palo Alto, CA). The percentage of cells in the various stages of the cell cycle was determined using the ModFitLT software. Fig. 1 . PDTC inhibits growth of four pancreatic adenocarcinoma cell lines (PaCa44 ♦, T3M4 ▪ , Panc1 ▵, CFPAC1 ○), but not that of primary fibroblasts (*). PDTC was added at the indicated concentrations for 24 h. Cell proliferation was determined using the crystal violet colorimetric assay as described in Materials and methods. Values are the means of triplicate wells from three independent experiments. 
Apoptosis
The percentage of apoptotic cells was evaluated by staining 2 × 10 5 cells with annexin V-FITC (Bender Med System, Vienna, Austria) and 5 μg/ml propidium iodide in binding buffer [10 mM HEPES/NaOH (pH 7.4), 140 mM NaOH, and 2. 2.6. Measurement of reactive oxygen species (ROS) production 2′,7′-Dichlorofluorescin (DCF) (Sigma), which is a non-fluorescent probe becoming highly fluorescent upon reaction with ROS, was used to evaluate intracellular ROS production. Briefly, 2 × 10 5 cells were incubated with 10 μM DCF at 37°C for 15 min and then fluorescence emission measured by flow cytometry (FACScalibur, Becton Dickinson).
Immunoblot analysis
Cells were collected, washed in phosphate-buffered saline, and resuspended in 20 mM HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 1 mM Na 3 VO 4 , and 1× protease inhibitor cocktail (Roche). After three freeze/ thaw cycles, the lysate was centrifuged at 14,000×g for 10 min at 4°C and the supernatant was used for Western blot. Protein concentration was measured with the Bradford protein assay reagent (Pierce) using bovine serum albumin as a standard. Twenty-five to fifty micrograms of protein extracts were electrophoresed through a 12% SDS-polyacrylamide gel and electro-blotted onto PVDF membranes (Millipore, Bedford, MA). Membranes were then incubated overnight at 4°C with blocking solution [5% low-fat milk in TBST (100 mM Tris, pH 7.5, 0.9% NaCl, 0.1% Tween 20)] and probed for 1 h at room temperature with the appropriate primary antibody (1:1000 in blocking solution). Horseradish peroxidase conjugated anti-mouse IgG (1:1000 in blocking solution, Upstate Biotechnology) was used to detect specific proteins. Immunodetection was carried out using chemiluminescent substrates (Amersham Pharmacia Biotech) and recorded using a HyperfilmECL (Amersham Pharmacia Biotech). The primary monoclonal antibodies used included antihuman ERK1/2 (Santa Cruz Biotechnology), anti-human phospho-ERK1/2 (Santa Cruz Biotechnology), anti-human p21 WAF1/CIP1 (Upstate Biotechnology), anti-human phospho-p53 (Ser15) (Cell Signaling Technology), or anti-human α-tubulin (Oncogene).
RNA extraction, RT-PCR, and image analysis
Total RNA was extracted from 5 × 10 6 cells using TRIzol Reagent (Invitrogen) and one μg was reverse transcribed using First Strand cDNA Synthesis (Invitrogen). For each sample, one tenth of the cDNAs was used as template for PCR amplifications using the following primers and cycling conditions: p21For 5′-GCGCTAATGGCGGGCTGCAT-3′ and p21Rev 5′-GCCGGCGTTTGGAGTGGTAG-3′, for 25 cycles of 94°C for 60 s, 53°C for 60 s and 72°C for 60 s; GPXFor 5′-CCAGTTTGGGCATCAGGAG-3′ and GPXRev 5′-CGATGTCAATGGTCTGGAAG-3′, SESN1For 5′-CGACCAG GACGAGGAACTT-3′ and SESN1Rev 5′-CCAATGTAGTGACGATAATG TAGG-3′, SESN2For 5′-TCCGCCACTCAGAGAAGGTC-3′ and SESN2Rev 5′-GTTCAGGAAGGCCACAACAC-3′, for 30 cycles of 94°C for 30 s, 58°C for 30 s and 72°C for 30 s; β-actinFor 5′-ACCAACTGGGACGACATGGA GAA-3′ and β-actinRev 5′-GTGGTGGTGAAGCTGTAGCC-3′, for 25 cycles of 94°C for 60 s, 55°C for 60 s and 72°C for 60 s. PCR products were separated by electrophoresis through an ethidium bromide stained 2.0% agarose gel and visualized with ultraviolet light. Gels were photographed and the bands were scanned as digital peaks. The areas of the peaks were calculated in arbitrary units using the public domain NIH Image software (http://rsb.info.nih.gov/nihimage/). The value of β-actin mRNA was used as a normalizing factor to evaluate the relative expression levels of P21 WAF1/CIP1 mRNA.
Transient transfection assay
Cells were seeded at a density of 2.5 × 10 5 cells in 6-well plates. After 24 h, cells were transfected using FuGENE6 Transfection Reagent (Roche) with 0.2 μg of a reporter plasmid containing the 2,400 bp upstream to the initiation transcription site of P21 WAF1/CIP1 inserted into the pGL3-Basic vector. At 6 h after transfection, cells were treated with 250 μM PDTC or 0.2 μM TSA for different time points. Cell lysates containing an equal amount of proteins were assayed for luciferase activity using the Luciferase Assay System (Promega).
In vivo studies
PaCa44 cells (5 × 10 6 cells for each mice) were s.c. injected into female nude mice (4 weeks of age, Harlan, Italy). One week after cell inoculation, 5 randomized animals for each experimental group received vehicle control (PBS) or PDTC (100 mg/kg or 200 mg/kg) by peritumoral injection twice weekly for 2 weeks. Tumour volume and body weight were biweekly recorded for each animal. The animal studies were approved by the Verona University Review Board.
Results
PDTC inhibits growth of pancreatic adenocarcinoma cell lines by cell cycle S-phase arrest
To test the effect of PDTC on the proliferation of pancreatic adenocarcinoma cells, we measured the percentage of cell growth in four p53-negative cell lines after 24 h treatment with increasing amount of PDTC, compared to untreated cells. PDTC inhibited the growth of all four cancer cell lines in a dose dependent manner, while it was ineffective on normal human fibroblasts (Fig. 1) .
The analysis of cell cycle distribution and apoptosis in PaCa44 cells showed that PDTC treatment for 24 h determined a 20% increase of cells in S phase and a corresponding reduction in G1 phase, compared to untreated cells ( Fig. 2A) , while it was unable to induce apoptosis (Fig. 2B) . Overlapping results were obtained with the three other pancreatic adenocarcinoma cell lines examined (data not shown).
PDTC inhibits cell growth by a ROS/ERK1/2 mediated mechanism
To explore the molecular mechanisms responsible for PDTC induced cell cycle arrest, we measured ROS levels after PDTC treatment. Fig. 3A shows that ROS levels were increased approximately 2 fold in PDTC-treated PaCa44 cell line, while they were not affected in normal fibroblasts. Complete depletion of ROS by the free radical scavenger NAC (Fig. 3A) was able to significantly increase the percentage of cell growth in PDTC treated cells (Fig. 3B) . That ROS production plays an important role in PDTC induced cytostatic effect was also confirmed by a dose dependent proliferation assay showing that NAC was able to reduce cell growth inhibition at each concentration of PDTC tested (data not shown). To further verify whether ROS production was responsible for the differential cytostatic effect by PDTC on PaCa44 cells and fibroblasts, we performed a proliferation assay using increasing amount of diethylmaleate (DEM), a known oxidant agent. As shown in Fig. 3C , DEM inhibited the growth of the adenocarcinoma cell line in a dose dependent manner, while it was ineffective on normal human fibroblasts.
It is known that in some cellular systems, such as smooth muscle, embryonic kidney, and prostate cancer cells, PDTC is able to inhibit cell cycle progression by MAP kinases activation [15] [16] [17] . To verify whether pathways including JNK, p38, and ERK1/2 were involved in growth inhibition of pancreatic cell lines by PDTC, we tested the effect of inhibitors of these kinases on the growth of PaCa44 cells. Only PD98059, an inhibitor of MEK/ERK1/2, was able to increase cell survival by PDTC, whereas the others were ineffective (Fig. 3B) . Moreover, the addition of NAC to PD98059 did not further increase cell survival, suggesting that ROS may be responsible for MEK/ ERK1/2 activation. Fig. 3D shows that PDTC was able to strongly induce ERK1/2 phosphorylation and that this event was inhibited in the presence of NAC, indicating that ERK1/2 induction by PDTC depends indeed on ROS production.
PDTC induces P21 WAF1/CIP1 expression in PaCa44 cells
To investigate whether p21 WAF1/CIP1 was involved in cell cycle arrest by PDTC, we performed an RT-PCR analysis on total RNAs extracted from PaCa44 cells and fibroblasts before and after treatment with PDTC. Fig. 4A shows that P21 WAF1/CIP1 mRNA was strongly induced by PDTC in PaCa44 cells, while it remained at the basal level in fibroblasts. Western blot analysis of p21 WAF1/CIP1 in PaCa44 cells well correlated with the observed levels of P21 WAF1/CIP1 mRNA (Fig. 4B) . To evaluate the functional role of p21 WAF1/CIP1 in cell growth inhibition by PDTC, we performed a cell proliferation assay using a phosphorothioate antisense oligonucleotide (p21AS) inhibiting the expression of P21 WAF1/CIP1 . Treatment with PDTC and p21AS led to a marked increase of cell survival when compared to PDTC alone, while treatment with the sense oligonucleotide (p21 S) did not modify cell growth inhibition by PDTC (Fig. 4C) . The activation of P21 WAF1/CIP1 and its functional role in cell growth inhibition by PDTC was also confirmed in T3M4 cells (data not shown). Altogether these data indicate that p21 WAF1/CIP1 plays a pivotal role in PDTCmediated growth arrest of pancreatic adenocarcinoma cells.
PDTC induces P21
WAF1/CIP1 expression post-transcriptionally via a ROS/ERK mediated mechanism
To define the molecular mechanisms of P21
WAF1/CIP1
mRNA induction by PDTC, we examined the effect of PDTC on a wild-type P21 WAF1/CIP1 promoter-luciferase fusion plasmid after transient transfection in PaCa44 cells. Following 8 h exposure to PDTC, luciferase activity from the promoterreporter plasmid was not increased compared to untreated cells (Fig. 5A) , while trichostatin A (TSA), a known inducer of P21 WAF1/CIP1 transcription [18] , significantly activated the promoter construct. This result suggested that P21 WAF1/CIP1 mRNA enhancement after PDTC treatment was not due to a transcriptional activation of the gene. Using actinomycin D treatment of the cells and RT-PCR analysis, we tested whether PDTC may affect the stability of P21 WAF1/CIP1 mRNA. mRNA also in the presence of actinomycin D and that the ratio of expression between control and actinomycin D treated cells was comparable to that obtained in the presence of PDTC. These data strongly suggest that PDTC increases P21 WAF1/CIP1 mRNA levels mainly by enhancing its stability.
To verify whether ROS mediated ERK1/2 induction was involved in P21 WAF1/CIP1 mRNA stabilization by PDTC, we treated the cells with NAC and PD98059 and evaluated the levels of the P21 WAF1/CIP1 messenger by RT-PCR. Fig. 5D shows that these compounds significantly reduced P21 WAF1/CIP1 induction by PDTC and that their combination did not further enhance this effect. These results, in line with data shown in Fig. 3 , demonstrate that ROS and ERK1/2 are involved in P21 WAF1/CIP1 mRNA induction by PDTC and provide evidence that both signals belong to the same pathway. As expected, treatment of cells with JNK and p38 inhibitors did not reduce P21 WAF1/CIP1 induction by PDTC.
PDTC induces p53 and the antioxidant SESN2 gene in fibroblasts
To determine whether p53 was involved in the resistance of fibroblasts to the cytotoxic action of PDTC, we performed a Western blot analysis on total cellular proteins from fibroblasts treated with PDTC, using antibodies specific for p53 phosphorylated at Ser15. As shown in Fig. 6A , PDTC was able to induce the phosphorylation of Ser15, which has been previously reported to mediate the activation of p53 by ROS [19, 20] . Then, we analyzed the effect of PDTC on the expression of the glutathione peroxidase 1 (GPX1), sestrin 1 (SESN1), and sestrin 2 (SESN2) genes, which are known to be up-regulated by p53 and encode products that act as antioxidants [21] . PDTC treatment of fibroblasts resulted in a 5.5 fold increase in SESN2 mRNA, whereas the levels of the other two mRNAs remained unchanged (Fig. 6B and C) . In contrast, in PaCa44 cells, which contain a non-functional TP53, GPX1, SESN1, and SESN2 were not regulated by PDTC. These results suggest that the resistance of fibroblasts to the cytotoxic action of PDTC may be related to the up-regulation of p53-dependent antioxidant genes that scavenge ROS production by PDTC.
PDTC inhibits pancreatic tumour growth in nude mice
The effect of PDTC on growth inhibition of pancreatic cancer cells in vivo was examined in nude mice bearing subcutaneous xenografts of PaCa44 cells. Seven days after s.c. injection of 5 × 10 6 PaCa44 cells, five mice for each group were randomized to receive biweekly peritumoral injection with PBS (vehicle control) or PDTC for 2 weeks. Fig. 7A and B shows that, at the end of the study period, PDTC determined at the dose of 100 mg/ kg or 200 mg/kg a reduction of the tumour volume of about 30% and 60%, respectively, compared to control. These treatments did not produce any toxicity as indicated by lack of change in mice body mass (Fig. 7C ).
Discussion
In this study, we have evaluated the in vitro and in vivo effects of PDTC on human pancreatic adenocarcinoma cell lines. We have demonstrated that PDTC strongly inhibits in vitro growth of p53-negative pancreatic adenocarcinoma cell lines by S-phase cell cycle arrest, while it is ineffective on normal primary fibroblasts. Furthermore, we have reported that PDTC increases intracellular ROS levels in PaCa44 cell line and strongly induces ROS-dependent ERK1/2 phosphorylation. This induction is largely responsible for the increased stability of P21 WAF1/CIP1 mRNA that plays a central role in PDTCmediated growth arrest of pancreatic cancer cells, as demonstrated by gene silencing with a P21 WAF1/CIP1 antisense oligonucleotide. In contrast, PDTC activates p53 and the p53-regulated antioxidant SESN2 in primary fibroblasts, which may be responsible for the resistance of these cells to the cytotoxic action of the drug. Fig. 8 shows a model of the molecular mechanisms deduced from our data.
Cellular oxidative stress induced by PDTC may have different origins: (i) increased intracellular concentration of metal bivalent ions, such as Zn 2+ , Cu 2+ , and Fe 2+ , via its ionophore activity [3, 4] ; (ii) inhibition of the (copper/zinc) superoxide dismutase activity, via its chelating activity [22] ; (iii) inhibition of the glutathione peroxidase activity [23] ; (iv) oxidation of PDTC by microsomal flavin-containing monooxygenases to the reactive intermediate sulfenic acid, which oxidizes GSH to GSSG by a nonenzymatic reaction [5] . Our unpublished data showing that the administration of the metal bivalent ion chelator N,N,N′,N′-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN) strongly reduces cell growth inhibition by PDTC suggest that ROS production by PDTC in pancreatic cancer cells is mainly due to its ionophore activity.
It has recently been reported that in the absence of severe stresses relatively low levels of p53 are sufficient for up-regulation of several genes encoding antioxidant proteins, which is associated with a decrease in intracellular ROS [21] . In the present study, we have demonstrated that in primary fibroblasts PDTC is able to induce a low level of p53 phosphorylation at Ser 15. In addition, we show that PDTC up-regulates the p53-dependent antioxidant SESN2 in fibroblasts but not in pancreatic adenocarcinoma cells, strongly suggesting that its antioxidant effect may scavenge ROS production by PDTC and renders fibroblasts resistant to the cytotoxic action of the drug. This observation is in line with the emerging belief on the protective functions of p53 under low stress conditions [21] .
Intracellular ROS production may regulate several mechanisms associated to the control of cell proliferation [24] , supporting the concept that ROS may be considered as second messengers [25] . In our cellular system, oxidative stress induced by PDTC determines a strong phosphorylation of ERK1/2, in line with the result obtained by Esposito et al. with diethylmaleate on HeLa cells [26] . ERK1/2 activation is totally inhibited by the antioxidant molecule NAC, demonstrating that it is strictly dependent on ROS production. Furthermore, NAC or PD98059 determine a significant reduction of cell growth inhibition by PDTC, demonstrating that the ROS/ERK pathway plays an important role in this process. However, as this effect is not complete, the ROS/ERK1/2 pathway may not be the only mechanism involved in cell growth inhibition by PDTC. We also report that the other two MAPKs, JNK and p38, do not play a role in cell growth inhibition by PDTC. p21 WAF1/CIP1 is one of most important regulators of the cell cycle [27] and its gene has rarely been found mutated in human cancers, including pancreatic cancer [28] . We show here that pancreatic cancer cell growth inhibition by PDTC is mediated by the increased stability of P21 WAF1/CIP1 mRNA. Our data correlate with the previously reported results describing P21 WAF1/CIP1 induction by ROS/ERK at post-transcriptional level [26] . Noteworthy, we have observed that the absence of ROS activation by PDTC in primary fibroblasts strictly correlates with lack of both P21 WAF1/CIP1 induction and cell growth inhibition. Recently, it has been reported that in breast cancer cells the epidermal growth factor increases P21 WAF1/CIP1 mRNA stability elicited via multiple 3′-UTR cis-elements [29] . This mechanism may also be involved in ERK1/2 dependent P21 WAF1/CIP1 induction by PDTC in pancreatic cancer cells.
Our results indicate that P21 WAF1/CIP1 induction inhibits Sphase progression, although p21 WAF1/CIP1 has been commonly associated with the arrest in G1 [15] or G2/M phases [30] of the cell cycle. However, it has also been observed that P21 WAF1/CIP1 up-regulation is required for S-phase arrest in human breast and ovarian cancer cells and that this arrest does not occur in P21 WAF1/CIP1−/− cells [31, 32] . Our in vivo experiments showed that peritumoral injections of PDTC into nude mice bearing a subcutaneous mass of pancreatic adenocarcinoma cells inhibit tumour growth at doses of 100 mg/kg or 200 mg/kg. It is noteworthy that these treatments did not determine any apparent form of toxicity in vivo, as no mice deaths, body weight variations or other apparent toxicity-related features were observed. These results correlate with the observation that PDTC determines a specific cyto-toxicity in vitro against tumour cells (our results and [8] ).
In conclusion, our data clearly demonstrate that PDTC specifically inhibits pancreatic adenocarcinoma cell growth in vitro by P21 WAF1/CIP1 mRNA stabilization mediated by ROS dependent ERK1/2 induction and that fibroblasts are protected from PDTC growth inhibition most likely because of the ROS scavenging activity of sestrin 2 induced by PDTC-activated p53. Furthermore, in vivo inhibition of xenografted pancreatic cancer cell growth by PDTC at non-toxic doses support a potential use of this compound or other drugs having similar stressing specific effects in clinical trials.
